Ascendis Pharma A/S
ASND · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $8,854 | $8,644 | $7,948 |
| - Cash | $539 | $494 | $518 | $560 |
| + Debt | $331 | $793 | $847 | $857 |
| Enterprise Value | – | $9,152 | $8,974 | $8,245 |
| Revenue | $214 | $158 | $101 | $174 |
| % Growth | 35.2% | 56.6% | -42% | – |
| Gross Profit | $191 | $127 | $83 | $160 |
| % Margin | 89.5% | 80.1% | 82.6% | 91.9% |
| EBITDA | -$53 | $2 | -$44 | -$38 |
| % Margin | -25% | 1.5% | -43.8% | -21.8% |
| Net Income | -$61 | -$39 | -$95 | -$38 |
| % Margin | -28.5% | -24.6% | -93.7% | -22.1% |
| EPS Diluted | -1 | -0.82 | -1.58 | -0.64 |
| % Growth | -22% | 48.1% | -146.9% | – |
| Operating Cash Flow | $2 | -$7 | -$14 | -$87 |
| Capital Expenditures | -$0 | -$4 | -$1 | -$0 |
| Free Cash Flow | $2 | -$12 | -$15 | -$88 |